{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-065899","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.018749+00:00","generated_at":"2026-06-01T07:38:06.360296+00:00","sec_items":["5.02","5.07","5.05","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress","bullets":["Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.","Svetlana Lucas and Sanjay Shukla elected as Class III directors with majority votes.","Ratification of Ernst & Young as independent auditor for FY2024 (54.5M for, 327K against).","Advisory approval of executive compensation (42.5M for, 398K against).","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipates completing enrollment in Q2 2024; final patient dosing may occur in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-065899","json":"https://secwatch.observer/filing/0000950170-24-065899.json","markdown":"https://secwatch.observer/filing/0000950170-24-065899.md","text":"https://secwatch.observer/filing/0000950170-24-065899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/0000950170-24-065899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/life-20240522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:38:06.360296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}